Aileron Therapeutics
Présence
Aileron Therapeutics est une société cotée sous le symbole boursier ALRN (US).
Acquisition, funding and merger involving Aileron Therapeutics.
Dirigeants
Voir l'organigramme avec ses 8 principaux dirigeants
Biographies les plus recherchées chez Aileron Therapeutics
- Brian Windsor, Director, President and Chief Executive Officer
- Reinhard Ambros, Director
- Josef Von Rickenbach, Chairman of the Board
Changements de dirigeants chez Aileron Therapeutics
- Brian Windsor qui était Chief Operating Officer and President, est promu Director, President and Chief Executive Officer (publié le 13 mars 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Aileron Therapeutics.
Biotechnologie
Aileron Therapeutics a 2 277 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Histogen has filed for bankruptcy protection (publié le 19 avril 2024).
- Bruker has announced the acquisition of NanoString Technologies (publié le 18 avril 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publié le 16 avril 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Aileron Therapeutics
- Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer ― Aileron
- Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 ― Aileron
- Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer ― Aileron
- Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer ― Aileron Therapeutics
- Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference ― Aileron Therapeutics
- Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 ― Aileron Therapeutics
- Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual
- Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights ― Aileron Therapeutics
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights ― Aileron Therapeutics
- Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference ― Aileron Therapeutics
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Aileron Therapeutics
- Aileron Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Aileron Therapeutics sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Manuel Aivado 
Appelez Aileron Therapeutics au +1 617...
